European principles of inhibitor management in patients with haemophilia: implications of new treatment options

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F20%3A00116531" target="_blank" >RIV/00216224:14110/20:00116531 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/20:00073047
Result on the web
<a href="https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8" target="_blank" >https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s13023-020-01511-8" target="_blank" >10.1186/s13023-020-01511-8</a>

Result language
angličtina
Original language name
European principles of inhibitor management in patients with haemophilia: implications of new treatment options
Original language description
In light of the rapidly changing landscape of haemophilia treatment, the authors of the position paper on the “European Principles of Inhibitor Management” published in 2018 (Table 1) now provide an update on the major impact of novel therapies that bypass and/or substitute clotting factor VIII (FVIII) and IX (FIX) in the care of haemophilia patients with FVIII- or FIXneutralizing allo-inhibitory antibodies (inhibitors).
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10603 - Genetics and heredity (medical genetics to be 3)

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)